
In episode 9 of ImmunoLogic, Kristopher Bosse, MD, and the cohosts discussed how immunotherapy is reshaping treatment for high-risk neuroblastoma.
Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, explains why chimeric antigen receptor (CAR) T-cell therapy has shown the most progress in acute lymphoblastic leukemia (ALL).
Bijal D. Shah, MD, medical oncology, of Moffit Cancer Center, explains why chimeric antigen receptor (CAR) T-cell therapy has shown the most progress in acute lymphoblastic leukemia (ALL).